Xeris Biopharma Holdings, Inc. announced a collaboration agreement with Merck, with an option to license Xeris' suspension-based formulation technology, XeriJect, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations. Terms of the agreement were not disclosed.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.705 USD | -3.12% | -2.84% | -27.23% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.23% | 261M | |
+24.17% | 562B | |
-6.41% | 358B | |
+18.78% | 322B | |
+7.70% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-11.29% | 149B | |
-6.87% | 146B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Pharmaceuticals Enters Collaboration Agreement With Merck